Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Prolific Machines | Emeryville | Series B | $50.0M | 2026-10-14 |
| heXem bio | New York | Seed | $10.4M | 2026-09-15 |
| Mendel.ai | San Jose | Series B | $40.0M | 2022-03-25 |
| Rybodyn | San Diego | Seed | $1.3M | 2026-07-23 |
| Avalo | Durham | Series A | $11.0M | 2025-03-06 |
| BioSapien | San Diego | Seed | $8.0M | 2024-12-13 |
| BioFluff | Paris | Seed | $2.5M | 2026-09-02 |
| Koniku | San Rafael | Series A | $37.0M | 2021-12-17 |
8 rows of the CSV in 5 of its 18 columns.
- The 57 SOSV SF & NY (Fka IndieBio) portfolio companies have raised $557.6M in total.
- 17 of them closed their most recent round in the last 12 months, $99.3M combined.
- The largest of those rounds is Prolific Machines' $50.0M Series B, dated October 2026.
- National Science Foundation is an investor in 3 of them, more than any other fund.
- Biotech is the most common sector, with 39 companies (68%).
- 63% were founded in 2020 or later; the median founding year is 2020.
- The most common team size is 1 to 10 employees (67% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
24 of 57| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Prolific Machines | Prolific Machines develops light-controlled gene expression systems for producing therapeutics. | Artificial intelligence | Emeryville, United States | Series B | $50.0M | 2026-10-14 | $147.0M | SOSV, Mayfield Fund, SOSV SF & NY (Fka IndieBio) +2 | 51 to 100 | 2020 |
| heXem bio | HexemBio develops a synthetic human Yolk Sac platform to rejuvenate blood stem cells and extend healthy lifespan. | Biotech | New York, United States | Seed | $10.4M | 2026-09-15 | $10.4M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2024 |
| BryoSphere | BryoSphere manufactures specialty chemicals using moss plants and biotechnology methods. | Biotech | Burnaby, Canada | Angel | $29K | 2026-09-08 | $29K | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2022 |
| BioFluff | BioFluff creates plant-based fur, shearling, and plush for the fashion, interior, and toy industries. | Biotech | Paris, France | Seed | $2.5M | 2026-09-02 | $3.2M | SOSV, SOSV SF & NY (Fka IndieBio), Joyance Partners +1 | 1 to 10 | 2022 |
| Rybodyn | Rybodyn develops therapeutics that train the immune system to detect and eradicate cancer. | Biotech | San Diego, United States | Seed | $1.3M | 2026-07-23 | $15.3M | SOSV, SOSV SF & NY (Fka IndieBio) | 11 to 50 | 2022 |
| Fermeate | Fermeate provides photomolecular fermentation technology that makes biomanufacturing more sustainable and efficient. | Biotech | San Francisco, United States | Seed | $2.5M | 2026-04-27 | $2.5M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2024 |
| TippingPoint Biosciences | TippingPoint Biosciences develops therapeutics that target genome packaging states in diseases such as cancer. | Biotech | San Francisco, United States | Seed | $4.5M | 2026-03-31 | $4.5M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2022 |
| BioLattice | BioLattice develops tissue healing solutions. | Biotech | Philadelphia, United States | Seed | $575K | 2026-03-30 | $585K | SOSV, SOSV SF & NY (Fka IndieBio), Startup302 | 1 to 10 | 2017 |
| FluoSphera | FluoSphera develops drugs. | Biotech | Geneva, Switzerland | Seed | $1.4M | 2026-01-12 | $3.9M | SOSV, SOSV SF & NY (Fka IndieBio), FONGIT Innovation Fund +2 | 1 to 10 | 2021 |
| Cayuga Biotech | Cayuga Biotech develops hemostatic drugs and devices for treating bleeding episodes. | Biotech | Bridgewater, United States | Seed | $5.0M | 2025-12-11 | $8.2M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2015 |
| OncoPrecision | OncoPrecision develops patient-centric therapeutic antibodies. | Biotech | New York, United States | Seed | $4.5M | 2025-11-24 | $11.1M | SOSV, SOSV SF & NY (Fka IndieBio), GRID EXPONENTIAL +2 | 11 to 50 | 2020 |
| Helex | Helex works on making gene editing safer. | Biotech | New York, United States | Seed | $3.5M | 2025-10-30 | $4.6M | SOSV, SOSV SF & NY (Fka IndieBio) | 11 to 50 | 2021 |
| Avalo | Avalo applies AI and evolutionary methods to plant biotechnology for a more sustainable food system. | Artificial intelligence | Durham, United States | Series A | $11.0M | 2025-03-06 | $14.9M | SOSV, SOSV SF & NY (Fka IndieBio), Alexandria Venture Investments +2 | 11 to 50 | 2020 |
| BioSapien | BioSapien is a biotech startup that provides a drug delivery platform for cancer treatment. | Biotech | San Diego, United States | Seed | $8.0M | 2024-12-13 | $45.1M | SOSV, National Science Foundation, SOSV SF & NY (Fka IndieBio) +2 | 1 to 10 | 2018 |
| Ceragen | Ceragen is a biotechnology company that boosts crop yields through plant microbiome engineering. | Biotech | Kitchener, Canada | Seed | $2.0M | 2024-07-16 | SOSV, SOSV SF & NY (Fka IndieBio), 1517 Fund +1 | 1 to 10 | 2021 | |
| Xias Bio | Xias Bio produces soluble, active recombinant proteins for formulators to improve gel and film formation. | Biotech | Glasgow, United Kingdom | Seed | $4.8M | 2024-05-01 | SOSV, SOSV SF & NY (Fka IndieBio) | 11 to 50 | 2020 | |
| Gozen Bioworks | Gozen Bioworks is a multidisciplinary materials science and design company. | Biotech | Istanbul, Turkey | Seed | $3.3M | 2023-10-25 | SOSV, SOSV SF & NY (Fka IndieBio), Happiness Capital +1 | 1 to 10 | 2020 | |
| Veloz Bio | Veloz Bio uses molecular farming to produce animal-free and alternative proteins. | Biotech | Monterrey, Mexico | Seed | $4.0M | 2023-08-31 | SOSV, SOSV SF & NY (Fka IndieBio), Santatera Capital | 1 to 10 | 2021 | |
| NotCo Unicorn | NotCo is a food tech company that uses artificial intelligence to make food from plants. | Artificial intelligence | Santiago, Chile | Series D | $70.0M | 2022-12-12 | SOSV, General Catalyst, SOSV SF & NY (Fka IndieBio) +2 | 101 to 250 | 2015 | |
| Mendel.ai | Mendel.ai combines machine precision and human judgment to advance clinical research. | Artificial intelligence | San Jose, United States | Series B | $40.0M | 2022-03-25 | $65.4M | SOSV, DCM Ventures, SOSV SF & NY (Fka IndieBio) +2 | 101 to 250 | 2017 |
| Koniku | Koniku combines synthetic biology with silicon to build machines that detect smells. | Artificial intelligence | San Rafael, United States | Series A | $37.0M | 2021-12-17 | $49.2M | SOSV, SoftBank Vision Fund, SOSV SF & NY (Fka IndieBio) +1 | 11 to 50 | 2015 |
| Quartolio | Quartolio uses autonomous discovery to analyze millions of scientific documents in real time. | Artificial intelligence | New York, United States | Seed | $34K | 2021-11-18 | $154K | Techstars, SOSV, MassChallenge +2 | 1 to 10 | 2016 |
| Biomage | Biomage provides single-cell analysis tools for life sciences research. | Biotech | Glasgow, United Kingdom | Seed | $850K | 2020-12-08 | SOSV, SOSV SF & NY (Fka IndieBio), Techstart Ventures +2 | 11 to 50 | 2019 | |
| aBioBot | aBioBot helps bio scientists make discoveries faster by shortening research timelines. | Biotech | Dublin, United States | Pre-seed | $50K | 2015-02-03 | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2015 |
Table 1. SOSV SF & NY (Fka IndieBio) portfolio companies: the 24 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 57.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Prolific Machines | Prolific Machines develops light-controlled gene expression systems for producing therapeutics. | Artificial intelligence | Emeryville, United States | Series B | $50.0M | 2026-10-14 | $147.0M | SOSV, Mayfield Fund, SOSV SF & NY (Fka IndieBio) +2 | 51 to 100 | 2020 |
| 2 | heXem bio | HexemBio develops a synthetic human Yolk Sac platform to rejuvenate blood stem cells and extend healthy lifespan. | Biotech | New York, United States | Seed | $10.4M | 2026-09-15 | $10.4M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2024 |
| 3 | Cayuga Biotech | Cayuga Biotech develops hemostatic drugs and devices for treating bleeding episodes. | Biotech | Bridgewater, United States | Seed | $5.0M | 2025-12-11 | $8.2M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2015 |
| 4 | OncoPrecision | OncoPrecision develops patient-centric therapeutic antibodies. | Biotech | New York, United States | Seed | $4.5M | 2025-11-24 | $11.1M | SOSV, SOSV SF & NY (Fka IndieBio), GRID EXPONENTIAL +2 | 11 to 50 | 2020 |
| 5 | TippingPoint Biosciences | TippingPoint Biosciences develops therapeutics that target genome packaging states in diseases such as cancer. | Biotech | San Francisco, United States | Seed | $4.5M | 2026-03-31 | $4.5M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2022 |
| 6 | Fermeate | Fermeate provides photomolecular fermentation technology that makes biomanufacturing more sustainable and efficient. | Biotech | San Francisco, United States | Seed | $2.5M | 2026-04-27 | $2.5M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2024 |
| 7 | BioFluff | BioFluff creates plant-based fur, shearling, and plush for the fashion, interior, and toy industries. | Biotech | Paris, France | Seed | $2.5M | 2026-09-02 | $3.2M | SOSV, SOSV SF & NY (Fka IndieBio), Joyance Partners +1 | 1 to 10 | 2022 |
| 8 | FluoSphera | FluoSphera develops drugs. | Biotech | Geneva, Switzerland | Seed | $1.4M | 2026-01-12 | $3.9M | SOSV, SOSV SF & NY (Fka IndieBio), FONGIT Innovation Fund +2 | 1 to 10 | 2021 |
| 9 | Rybodyn | Rybodyn develops therapeutics that train the immune system to detect and eradicate cancer. | Biotech | San Diego, United States | Seed | $1.3M | 2026-07-23 | $15.3M | SOSV, SOSV SF & NY (Fka IndieBio) | 11 to 50 | 2022 |
| 10 | BioLattice | BioLattice develops tissue healing solutions. | Biotech | Philadelphia, United States | Seed | $575K | 2026-03-30 | $585K | SOSV, SOSV SF & NY (Fka IndieBio), Startup302 | 1 to 10 | 2017 |
Table 2. SOSV SF & NY (Fka IndieBio) portfolio companies: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 3 | 5% | ||
| 2 | MassChallenge Switzerland | Startup accelerator | Renens, Switzerland | 3 | 5% | ||
| 3 | Plug and Play | Startup accelerator | Sunnyvale, United States | 2 | 4% | 1 | Prellis Biologics |
| 4 | Genesis Consortium | Venture capital firm | Princeton, United States | 2 | 4% | ||
| 5 | Techstars | Startup accelerator | New York, United States | 2 | 4% | ||
| 6 | GRID EXPONENTIAL | Startup accelerator | Buenos Aires, Argentina | 2 | 4% | 1 | OncoPrecision |
| 7 | Breakthrough Energy Ventures | Venture capital firm | Paris, France | 1 | 2% | 1 | Prolific Machines |
| 8 | Breyer Capital | Venture capital firm | Menlo Park, United States | 1 | 2% | 1 | Prolific Machines |
| 9 | Mayfield Fund | Venture capital firm | Menlo Park, United States | 1 | 2% | 1 | Prolific Machines |
| 10 | Cantos | Micro VC fund | San Francisco, United States | 1 | 2% | 1 | Prellis Biologics |
| 11 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 1 | 2% | 1 | Prellis Biologics |
| 12 | DCM Ventures | Venture capital firm | Menlo Park, United States | 1 | 2% | ||
| 13 | BootstrapLabs | Venture capital firm | San Francisco, United States | 1 | 2% | ||
| 14 | Oak HC/FT | Private equity firm | Stamford, United States | 1 | 2% |
Table 3. SOSV SF & NY (Fka IndieBio) portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 39 | 68% | $499.5M |
| Health care | 25 | 44% | $492.7M |
| Software | 15 | 26% | $299.6M |
| Artificial intelligence | 9 | 16% | $280.6M |
| Hardware | 3 | 5% | $19.0M |
| Energy | 1 | 2% | $750K |
Table 4. SOSV SF & NY (Fka IndieBio) portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. SOSV SF & NY (Fka IndieBio) portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United States | 43 | 75% |
| United Kingdom | 3 | 5% |
| Mexico | 2 | 4% |
| Canada | 2 | 4% |
| France | 1 | 2% |
| Switzerland | 1 | 2% |
| Chile | 1 | 2% |
| Turkey | 1 | 2% |
| Estonia | 1 | 2% |
| Argentina | 1 | 2% |
Table 6. SOSV SF & NY (Fka IndieBio) portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| New York | 9 | 16% |
| San Francisco | 9 | 16% |
| San Diego | 3 | 5% |
| San Rafael | 2 | 4% |
| Glasgow | 2 | 4% |
| Emeryville | 1 | 2% |
| Berkeley | 1 | 2% |
| San Jose | 1 | 2% |
| Durham | 1 | 2% |
| Paris | 1 | 2% |
| Davis | 1 | 2% |
| Geneva | 1 | 2% |
Table 7. SOSV SF & NY (Fka IndieBio) portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 1 | 6% | $50.0M |
| September 2026 | 4 | 24% | $12.9M |
| August 2026 | 1 | 6% | |
| July 2026 | 1 | 6% | $1.3M |
| May 2026 | 2 | 12% | |
| April 2026 | 1 | 6% | $2.5M |
| March 2026 | 2 | 12% | $5.1M |
| January 2026 | 2 | 12% | $7.4M |
| December 2025 | 2 | 12% | $15.5M |
| November 2025 | 1 | 6% | $4.5M |
Table 8. SOSV SF & NY (Fka IndieBio) portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 14 | 25% | $79.3M |
| 2025 | 10 | 18% | $39.7M |
| 2024 | 16 | 28% | $24.6M |
| 2023 | 7 | 12% | $26.5M |
| 2022 | 4 | 7% | $110.0M |
| 2021 | 3 | 5% | $37.0M |
Table 9. SOSV SF & NY (Fka IndieBio) portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 12 | 21% |
| 2020 to 2022 | 24 | 42% |
| 2015 to 2019 | 20 | 35% |
| Before 2010 | 1 | 2% |
Table 10. SOSV SF & NY (Fka IndieBio) portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 38 | 67% |
| 11 to 50 | 15 | 26% |
| 51 to 100 | 1 | 2% |
| 101 to 250 | 2 | 4% |
| 251 to 500 | 1 | 2% |
Table 11. SOSV SF & NY (Fka IndieBio) portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when SOSV SF & NY (Fka IndieBio) is recorded as one of its investors. On 16 November 2026 that is 57 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 24 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 57 rows: 26 have no round amount, 1 no city and 6 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many SOSV SF & NY (Fka IndieBio) portfolio companies are on the list?
- 57, in the file dated 16 November 2026. 17 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 57 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.